Hunan Er-Kang Pharmaceutical Co., Ltd. Class A

Hunan Er-Kang Pharmaceutical Co., Ltd. Class A

SSZSE:300267
2.73
CNY
-0.06
(-2.15%)
-0.18EPS
6.72BMarket Cap
Hunan Er-Kang Pharmaceutical Co., Ltd. Class A
SZSE:300267
(Shenzhen Stock Exchange)

Recent

price

2.73

P/E

ratio

- -

div

yld

0.18%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.27
0.39
0.46
0.56
0.76
1.92
1.31
1.37
1.14
1.33
1.15
1.08
0.91
0.86
0.55
0.57
0.54
Revenue per Share
0.05
0.08
0.08
0.11
0.16
0.66
0.39
0.25
0.1
0.08
0.09
-0.38
0.02
-0.09
-0.18
-0.18
-0.17
Basic EPS, GAAP
-0.02
0.02
-0.08
-0.02
-0.2
-0.06
-0.32
0.21
0.01
0.04
-0.23
-0.12
0.05
-0.04
-0.01
0.05
- -
Free Cash Flow per Basic Share
- -
- -
0.03
0.01
0.02
0.08
0.05
0.02
0.02
0.01
0.02
0.06
- -
0.03
- -
0.01
- -
Dividend per Share
0.13
0.58
0.64
0.73
0.89
2.03
2.4
2.6
2.71
2.82
2.82
2.35
2.45
2.34
2.16
1.96
1.98
Book Value per Share
0.11
0.57
0.62
0.7
0.78
1.92
2.25
2.46
2.58
2.6
2.59
2.14
2.25
2.16
1.98
1.8
1.83
Tangible Book Value per Share
1,368
1,544
1,804
1,795
1,802
916
2,058
2,063
2,063
2,062
2,063
2,063
2,060
2,063
2,063
2,063
2,059
Basic Weighted Avg Shares
364
608
835
1,011
1,370
1,756
2,706
2,828
2,354
2,744
2,382
2,235
1,871
1,783
1,140
1,166
1,106
Sales/Revenue/Turnover
23.01
21.91
20.26
21.69
24.8
36.96
30.29
25.09
15.57
7.14
6.13
2.65
1.05
-4.69
-4.74
1.35
5.53
Operating Margin (%)
10
14
18
36
70
91
111
128
131
157
191
197
176
204
197
181
- -
Depreciation Expense
66
118
152
193
288
605
795
522
217
159
192
-791
46
-195
-373
-380
-347
Net Income, GAAP
14.15
14.53
15.23
14.01
14.37
9.13
9.36
12.83
21.87
11.8
10.01
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
18.26
19.36
18.2
19.09
21.04
34.43
29.39
18.48
9.2
5.78
8.07
-35.4
2.46
-10.95
-32.76
-32.58
-31.39
Profit Margin (%)
31
881
796
773
663
2,544
1,902
2,481
2,780
2,484
1,929
1,447
1,366
1,128
1,012
986
1,009
Working Capital
- -
- -
- -
- -
200
- -
- -
- -
- -
- -
2
2
3
1
17
28
25
LT Debt
177
1,062
1,164
1,334
1,678
4,257
4,996
5,412
5,639
5,853
5,838
4,874
5,051
4,810
4,402
3,974
4,011
Total Equity
33.12
17.47
13.53
15.37
16.69
18.08
15.82
9.89
4.96
2.8
3.24
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
35.43
18.53
13.67
15.38
17.4
19.14
17.15
10.28
4.04
2.92
3.52
- -
- -
- -
- -
- -
- -
Return on Capital (%)
46.81
19.08
13.7
15.53
19.56
20.83
17.45
10.14
3.95
2.78
3.31
-14.84
0.93
-3.95
-8.04
-8.96
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
689
697
677
LT Borrowings
- -
- -
- -
LT Finance Leases
28
24
25
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,063
2,063
2,063
Market Capitalization
8,106
6,807
6,724

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,919
1,974
1,962
Cash, Cash Equivalents & STI
1,067
904
960
Accounts Receivable, Net
129
156
122
Inventories
524
750
695
Total Current Liabilities
917
950
954
Payables & Accruals
- -
- -
- -
ST Debt
689
697
677
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.25%
-7.17%
-9.73%
Free Cash Flow
-43.58%
-172.83%
-424.15%
Net Income, GAAP
-111.64%
-209.89%
1.73%
Sales/Revenue/Turnover
-1.57%
-12.19%
2.29%
Total Cash Common Dividend
143.14%
281.42%
31.82%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
276
346
233
285
1,140
2025
354
328
- -
159
1,166
2026
247
320
379
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
-0.02
-0.17
-0.18
2025
0.01
- -
- -
-0.2
-0.18
2026
0.01
0.02
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Business
Hunan Er-Kang Pharmaceutical Co., Ltd. (300267.SZ) manufactures and sells pharmaceutical excipients, active pharmaceutical ingredients (APIs), and finished drugs. The company produces over 120 types of pharmaceutical excipients including medicinal ethanol, medicinal glycerin, modified starch, starch capsule series products, citric acid series, sucrose, and compound excipients; 43 APIs such as dihydroxypropyl theophylline, sulbenicillin sodium, and calamine powder; and 148 finished drug approvals encompassing hemostatic, antitussive, bronchodilator, antibacterial injections, compound licorice tablets, methyl benzyl amoxicillin sodium injections, manna ghee pills, and pancreatic kinase enteric tablets. Founded in 2003 and headquartered in Liuyang, Hunan province, China, the company operates as China's largest and most comprehensive pharmaceutical excipient provider with products exported to nearly 40 countries across Southeast Asia, Europe, and North America. It maintains 14 subsidiaries including Hunan Xiang Yi Kang Pharmaceutical Co., Ltd., Nanning Gui Zhilong Pharmaceutical Excipient Co., Ltd., and Hunan Er-Kang (Cambodia) Investment Co., Ltd., which supports an industrial park in Cambodia producing pharma-grade cassava starch, caffeine, folic acid, and sodium citrate. Er-Kang relies on national platforms like the National Pharmaceutical Excipients Engineering Technology Research Center and National Enterprise Technology Center for innovation in areas such as starch-based plant capsules, which hold global exclusive intellectual property rights with over 90 patents. Recent developments include strong first-quarter 2025 financial performance with net income surging 869% year-on-year, plans for a share distribution of 10 shares for every 8 held in 2024, and passage of annual audits from major clients like Johnson & Johnson and Mentholatum in 2025. The company continues expanding its starch capsule market, including successful entry into the Middle East, while maintaining operations in new energy fund materials alongside its core pharmaceutical segments.